ZENAS BIOPHARMA ($ZBIO) posted quarterly earnings results on Tuesday, August 12th. The company reported earnings of -$1.25 per share, missing estimates of -$1.07 by $0.18. The company also reported revenue of $0, missing estimates of $1,275,000 by $-1,275,000.
You can see Quiver Quantitative's $ZBIO stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ZENAS BIOPHARMA Analyst Ratings
Wall Street analysts have issued reports on $ZBIO in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 05/16/2025
- Wedbush issued a "Outperform" rating on 03/20/2025
- Guggenheim issued a "Buy" rating on 03/12/2025
To track analyst ratings and price targets for ZENAS BIOPHARMA, check out Quiver Quantitative's $ZBIO forecast page.
ZENAS BIOPHARMA Price Targets
Multiple analysts have issued price targets for $ZBIO recently. We have seen 3 analysts offer price targets for $ZBIO in the last 6 months, with a median target of $35.0.
Here are some recent targets:
- Matthew Caufield from HC Wainwright & Co. set a target price of $30.0 on 05/16/2025
- Martin Fan from Wedbush set a target price of $35.0 on 03/20/2025
- Yatin Suneja from Guggenheim set a target price of $45.0 on 03/12/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
